切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2023, Vol. 17 ›› Issue (03) : 143 -150. doi: 10.3877/cma.j.issn.1674-0807.2023.03.003

论著

利用CRISPR/Cas9基因编辑技术构建敲除4EBP1基因的乳腺癌细胞系
鄢宛玉, 张哲, 罗国兰, 黄芳, 郑红(), 李山虎   
  1. 230032 合肥,安徽医科大学基础医学院
  • 收稿日期:2022-07-24 出版日期:2023-06-01
  • 通信作者: 郑红
  • 基金资助:
    安徽省高校协同创新项目(GXXT-2021-063)

Construction of 4EBP1 knockout breast cancer cell lines using CRISPR/Cas9 gene editing technology

Wanyu Yan, Zhe Zhang, Guolan Nuo, Fang Huang, Hong Zheng(), Shanhu Li   

  1. School of Basic Medicine, Anhui Medical University, Hefei 230032, China
  • Received:2022-07-24 Published:2023-06-01
  • Corresponding author: Hong Zheng
引用本文:

鄢宛玉, 张哲, 罗国兰, 黄芳, 郑红, 李山虎. 利用CRISPR/Cas9基因编辑技术构建敲除4EBP1基因的乳腺癌细胞系[J/OL]. 中华乳腺病杂志(电子版), 2023, 17(03): 143-150.

Wanyu Yan, Zhe Zhang, Guolan Nuo, Fang Huang, Hong Zheng, Shanhu Li. Construction of 4EBP1 knockout breast cancer cell lines using CRISPR/Cas9 gene editing technology[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(03): 143-150.

目的

利用规律性重复短回文序列簇/相关基因9(CRISPR/Cas9)编辑技术构建真核翻译起始因子4E结合蛋白1(4EBP1)基因敲除的人乳腺癌MCF-7、ZR-75-1细胞系。

方法

设计能特异性针对4EBP1基因的特异性向导RNA(sgRNA),以lentiCRISPR v2质粒为骨架构建能表达sgRNA和Cas9蛋白的重组质粒。测序鉴定后将重组质粒与逆转录病毒包装质粒pMD2.G、psPAX2共同转入HEK 293T细胞进行慢病毒包装,收集病毒上清感染人乳腺癌MCF-7、ZR-75-1细胞。利用嘌呤霉素筛选4EBP1表达缺失的MCF-7、ZR-75-1细胞,DNA测序和Western blot验证。在MCF-7、ZR-75-1野生型与4EBP1基因敲除的细胞中转入pcDNA3-rluc-poli-IRESfluc质粒,并用双荧光素酶报告基因实验检测4EBP1、4EBP1不同突变体对帽子依赖翻译的影响,以海肾荧光素酶与萤火虫荧光素酶比值(R/F比值)来表示帽子依赖的翻译水平。R/F比值的组间比较采用t检验,两两比较采用LSD法。

结果

Western blot结果显示构建的3种lentiCRISPR v2-4EBP1-KO重组质粒转染MCF-7、ZR-75-1细胞后,4EBP1蛋白的表达水平均明显降低,说明4EBP1基因敲除成功。DNA测序发现MCF-7细胞的DNA序列中sgRNA出现了T碱基的插入突变,在ZR-75-1细胞DNA序列中sgRNA出现了GC碱基的缺失突变,证明细胞基因组DNA中的基因编辑成功。野生型和4EBP1基因敲除的ZR-75-1细胞中测得的R/F比值分别为1.83±0.10和5.48±0.33,组间比较差异有统计学意义(t=-18.338,P<0.001)。野生型和4EBP1基因敲除的MCF-7细胞中测得的R/F比值分别为1.17±0.06和2.03±0.20,组间比较差异有统计学意义(t=-7.167,P<0.001)。4EBP1基因敲除、敲除后分别转染4EBP1、plv-neo-4EBP1-37/46和plv-neo-4EBP1-4A的4种ZR-75-1细胞中测得的R/F比值分别为5.48±0.33、3.83±0.10、3.53±0.23和1.87±0.05,组间比较差异有统计学意义(F=151.995,P<0.001);4种MCF-7细胞中测得的R/F比值分别为2.03±0.200、1.37±0.14、1.90±0.19和1.20±0.17,组间比较差异有统计学意义(F=5.744,P=0.001)。

结论

4EBP1基因敲除乳腺癌细胞系可用于后续不同4EBP1磷酸化突变体对翻译起始作用的进一步研究。

Objective

To construct the eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) gene knockout human breast cancer MCF-7 and ZR-75-1 cell lines using clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated 9 (Cas9) gene editing technology.

Methods

We designed a sequence-specific guide RNA (sgRNA) that specifically targeted the 4EBP1 gene, and used the lentiCRISPR v2 plasmid as a backbone to construct a recombinant plasmid that expressed sgRNA and Cas9 protein. After sequencing and identification, the recombinant plasmid was co-transferred into HEK 293T cells with retroviral packaging plasmids pMD2.G and psPAX2 for lentiviral packaging, and viral supernatants at 24 h and 48 h were collected to infect human breast cancer MCF-7 and ZR-75-1 cells. MCF-7 and ZR-75-1 cells with deletion of 4EBP1 were screened out using puromycin, and verified by DNA sequencing and Western blot analysis. The MCF-7, ZR-75-1 wild-type and 4EBP1 knockout cells were transfected with pcDNA3-rluc-poli-IRESfluc plasmid. The effects of different mutants of 4EBP1 on cap-dependent translation were detected using a dual luciferase reporter gene assay and the cap-dependent translation level was expressed as the ratio of renilla luciferase to firefly luciferase (R/F ratio). The t-test was used to compare the R/F ratio between groups, and the LSD method was used for pairwise comparisons.

Results

Western blot analysis showed that the expression levels of 4EBP1 protein were significantly reduced in MCF-7 and ZR-75-1 cells transfected with the three constructed lentiCRISPR v2-4EBP1-KO plasmids, indicating successful knockdown of 4EBP1 gene. DNA sequencing revealed a T-base insertion of sgRNA in the DNA sequence of MCF-7 cells, and a GC-base deletion of sgRNA in the DNA sequence of ZR-75-1 cells, demonstrating the success of gene editing in the cellular genomic DNA. The R/F ratios measured in wild-type and 4EBP1 knockout ZR-75-1 cells were 1.83±0.10 and 5.48±0.33, respectively, suggesting a significant difference between two groups (t=-18.338, P<0.001). The R/F ratios measured in wild-type and 4EBP1 knockout MCF-7 cells were 1.17±0.06 and 2.03±0.20, respectively, suggesting a significant difference between two groups (t=-7.167, P<0.001). The R/F ratios measured in ZR-75-1 cells with 4EBP1 knockout, and ZR-75-1 cells transfected with 4EBP1, plv-neo-4EBP1-37/46 and plv-neo-4EBP1-4A were 5.48±0.33, 3.83±0.10, 3.53±0.23 and 1.87±0.05, respectively, suggesting a significant difference between groups (F=151.995, P<0.001); the corresponding R/F ratios measured in MCF-7 cells were 2.03±0.200, 1.37±0.14, 1.90±0.19 and 1.20±0.17, respectively, suggesting a significant difference between groups (F=5.744, P=0.001).

Conclusion

The 4EBP1 knockout breast cancer cell lines can be used for the studies on the role of different 4EBP1 phosphorylation mutants on translation initiation.

表1 识别4EBP1基因靶位点的sgRNA序列设计
表2 构建靶向真核翻译起始因子4E结合蛋白1基因质粒的退火体系
表3 构建靶向真核翻译起始因子4E结合蛋白1基因质粒的退火反应条件
表4 lentiCRISPR v2-4EBP1-KO重组质粒鉴定的PCR反应程序
表5 lentiCRISPR v2-4EBP1-KO 3#质粒基因PCR扩增反应程序
图1 质粒lentiCRISPR v2酶切电泳图注:12 988 bp为lentiCRISPR v2质粒空载体
图2 DH10b菌液鉴定电泳图注:1#、2#、3#分别代表lentiCRISPR v2-4EBP1-KO 1#、2#、3#质粒
图3 质粒lentiCRISPR v2-4EBP1-KO测序结果 a、b、c图分别为lentiCRISPR v2-4EBP1-KO 1#、2#、3#重组质粒的测序结果注:12 988 bp为lentiCRISPR v2质粒空载体;sgRNA为特异性向导RNA
图4 人乳腺癌MCF-7、ZR-75-1细胞DNA测序结果 a图为MCF-7细胞测序结果,基因组中出现了T碱基的插入突变;b图为ZR-75-1细胞测序结果,基因组中出现了GC碱基的缺失突变注:sgRNA为特异性向导RNA
图5 Western blot检测4EBP1在乳腺癌细胞MCF-7、ZR-75-1中的表达 a、b图分别为乳腺癌细胞ZR-75-1和MCF-7中3种lentiCRISPR v2-4EBP1-KO重组质粒敲除后4EBP1蛋白表达水平注:WT为野生型细胞;1#、2#、3#分别为lentiCRISPR v2-4EBP1-KO 1#、2#、3#质粒转染进细胞后提取的蛋白样本;4EBP1为真核翻译起始因子4E结合蛋白1;tubulin为微管蛋白
图6 Western blot检测4EBP1基因敲除的ZR-75-1、MCF-7细胞4EBP1磷酸化突变后的4EBP1表达水平注:WT为野生型细胞;4EBP1为真核翻译起始因子4E结合蛋白1;tubulin为微管蛋白
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin20211(3):209-249.
[2]
Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy[J]. J Hematol Oncol, 2019, 12(1):71.
[3]
Shi Y, Zhou C, Lu H, et al. Ceramide synthase 6 predicts poor prognosis and activates the AKT/mTOR/4EBP1 pathway in high-grade serous ovarian cancer[J]. Am J Transl Res, 2020, 12(9):5924-5939.
[4]
An QW, Nicolaides TP, Weiss WA. Inhibiting 4EBP1 in glioblastoma[J]. Clin Cancer Res2018, 24(1):14-21.
[5]
Merrick WC. eIF4F: a retrospective[J].J Biol Chem, 2015, 290(40):24 091-24 099.
[6]
Fan Q, Aksoy O, Wong RA, et al. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma[J]. Cancer Cell, 2017, 31(3):424-435.
[7]
Rutkovsky AC, Yeh ES, Guest ST,et al. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer[J]. BMC Cancer, 2019, 19(1):491.
[8]
Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes[J].Nat Biotechnol, 2014, 32(4):347-355.
[9]
Sen ND, Zhou F, Harris MS, et al. eIF4B stimulates translation of long mRNAs with structured 5′ UTRs and low closed-loop potential but weak dependence on eIF4G[J]. Proc Natl Acad Sci USA, 2016, 113(38):10 464-10 472.
[10]
Romagnoli A, D’Agostino M, Ardiccioni C, et al. Control of the eIF4E activity: structural insights and pharmacological implications[J]. Cell Mol Life Sci, 2021, 78(21-22):6869-6885.
[11]
Böhm R, Imseng S, Jakob RP, et al. The dynamic mechanism of 4E-BP1 recognition and phosphorylation by mTORC1[J]. Molecular Cell, 2021, 81(11):2403-2416.e5.
[12]
Saramäki O, Willi N, Bratt O, et al Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer[J]. Am J Pathol, 2001, 159(6):2089-2094.
[13]
Marash L, Liberman N, Henis-Korenblit S, et al. DAP5 promotes cap-independent translation of Bcl-2 and CDK1 to facilitate cell survival during mtosis[J]. Mol Cell, 2008, 30(4):447-459.
[14]
Tiu GC, Kerr CH, Forester CM, et al. A p53-dependent translational program directs tissue-selective phenotypes in a model of ribosomopathies[J]. Develop Cell, 2021, 56(14):2089-2102.
[15]
Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers[J]. Clin Cancer Res, 2004, 10(20): 6779-6788.
[16]
Luo W, Wang F, Luo H, et al. Arctigenin inhibits human breast cancer cell proliferation, migratory and invasive abilities and epithelial to mesenchymal transition by targeting 4EBP1[J]. Exp Ther Med, 2021, 21(6): 547.
[17]
Karlsson E, Pérez-Tenorio G, Amin R, et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised stockholm tamoxifen trials[J]. Breast Cancer Res, 2013, 15(5): R96.
[18]
Naito S, Ichiyanagi O, Ito H, et al. Expression of total and phospho 4EBP1 in metastatic and non-metastatic renal cell carcinoma[J]. Oncol Lett, 2019, 17(4): 3910-3918
[19]
Ma Y, Zhang L, Huang X. Genome modification by CRISPR/Cas9[J]. FEBS J, 2014, 281(23):5186-5193.
[20]
Rasmussen SB, Kordon E, Callahan R, et al. Evidence for the transforming activity of a truncated Int6 gene, in vitro[J]. Oncogene, 2001, 20(38): 5291-5301.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要